What question did this study set out to answer?

This research aims to evaluate long-term survival rates and treatment-related side effects in primary CNS lymphoma patients treated with combined modality therapy.

March 1, 1998Journal of Clinical Oncology

Long-term survival in primary CNS lymphoma.

View Full Paper

Ask AI

Bookmark

This research aims to evaluate long-term survival rates and treatment-related side effects in primary CNS lymphoma patients treated with combined modality therapy.
Follow-up analysis of 31 patients treated from 1986 to 1992 with methotrexate, cranial radiotherapy, and high-dose cytarabine.
Assessment of median cause-specific survival and disease-free survival, along with late treatment-related toxicity.
Comparative analysis against historical controls treated with radiotherapy alone.
Median cause-specific survival was 42 months with a five-year survival of 22.3%, compared to 3% to 4% in historical controls.
Age under 50 years at diagnosis significantly correlated with better survival (P = .01).
Late treatment-related toxicity occurred in nearly one third of patients, with a significantly higher risk for those over 60 (P < .0001).

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Follow-up analysis reveals improved survival and toxicity concerns in primary CNS lymphoma patients.

Cite This Study

Abrey et al. (1998) studied this question.

synapsesocial.com/papers/6a627fcc5a5e300a328a11eb https://doi.org/10.1200/jco.1998.16.3.859

View Full Paper

Ask AI

Bookmark

Long-term survival in primary CNS lymphoma.

Key Points

Discussion

Implication

Cite This Study

Long-term survival in primary CNS lymphoma.

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider